Clinical guidelines for the treatment of cancer-related anemia

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 156-169

  Koeller, Jim M ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANOREXIA; CANCER PATIENT; CLINICAL TRIAL; CRYSTALLOID; DIARRHEA; DYSPNEA; EDEMA; ERYTHROCYTE CONCENTRATE; FATIGUE; HEMOLYSIS; HUMAN; HYPERTENSION; INJECTION PAIN; MAJOR CLINICAL STUDY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; VERTIGO;

ANEMIA; BLOOD TRANSFUSION; EPOETIN ALFA; HEMATINICS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES;

EID: 0031964226     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Guyton AC. Red blood cells, anemia and polycythemia. In: Guyton AC, ed. Textbook of medical physiology. Philadelphia: WB Saunders, 1991:356-64.
2. Spivak, JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and survival factor. Blood 1991;77:1228-33.
3. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-81.
4. Egrie JC, Cotes PM, Lane J, Gaines Das RE, Tam RC. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods 1987;99:235-41.
5. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cell in murine kidneys by in situ hybridization. Blood 1988;71:524-27.
6. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988;81:620-3.
7. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA and serum erythropoietin concentration. Blood 1989;74:645-51.
8. Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77:2497-503.
9. Robinson SH. Physiology of hematopoiesis. In: Robinson SH, Reich PR, eds. Hematology: pathophysiologic basis for clinical practice. Boston: Little, Brown, 1993:1-13.
10. Despopoulos A, Silbernagl S. Color atlas of physiology, 4th ed. New York: Thieme Medical Publishers, 1991:61.
11. Rieger PT. Anemia - the forgotten problem. In: Fighting fatigue: resolving issues for the cancer patient [monograph]. Beachwood, OH: ProED Communications, 1994:2-12.
12. Bunn HF. Anemia. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., eds. Harrison's principles of internal medicine, 12th ed. New York: McGraw-Hill, 1991:344-8.
13. Roodman GD. Anemia of malignancy. In: Anemia: current issues [monograph]. Glenside, PA: Toltzis Communications, 1991:3:3-5.
14. Steinberg D. Anemia and cancer. CA Cancer J Clin 1989;39:296-304.
15. Wood P, Nygaard S, Hrushesky WJM. Cisplatin-induced anemia is correctable with erythropoietin [abstr]. Blood 1988;72(suppl 1):52a.
16. Doweiko JP, Goldberg MA. Erythropoietin therapy in cancer patients. Oncology 1991;5:31-7.
17. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
18. Marani TM, Tricb MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996;36: 1016-18.
19. Wurnig C, Windhager R, Schwameis E, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996;36:155-9.
20. Henry DH, Brooks BJ, Case DC, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-60.
21. Gastineau DA, Hoagland HC. Hematologic effects of chemotherapy. Semin Oncol 1992;19:543-50.
22. Sears DA. Anemia of chronic disease. Med Clin North Am 1992;76:567-9.
23. Johnson RA, Roodman GD. Hematologic manifestations of malignancy. Dis Mon 1990;35:721-68.
24. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966;3:351-75.
25. Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belg 1996;51:36-52.
26. Bentley DP, Cavill I, Ricketts C, Peake S. A method for the investigation of reticuloendothelial iron kinetics in man. Br J Haemotol 1979;43:619-24.
27. Freireich EF, Miller A, Emerson CP, Ross JF. The effect of inflammation on the utilization of erythrocyte and transferrin bound radioiron for red cell production. Blood 1957;12: 972-83.
28. Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987;66:559-64.
29. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989;261:3104-7.
30. Jelkmann W, Page H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992;50:301-8.
31. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-94.
32. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-47.
33. Lutton JD, Levere RD. Suppressive effect of human interferons on erythroid colony growth in disorders of erythropoiesis. J Lab Clin Med 1980;96:328-33.
34. Means RT Jr, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 1992;150:59-64.
35. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEBJ 1989;3:1637-43.
36. Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987;15:928-35.
37. Mamus SW, Beck-Schroeder S, Zanjani E. Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. J Clin Invest 1985;75:1496-1503.
38. Varat MA, Adolph RJ, Fowler NO. Cardiovascular effects of anemia. Am Heart J 1972;83:415-26.
39. Reiger PT, Haeuber D. A new approach to managing chemotherapy-related anemia: nursing implications of epoetin alfa. Oncol Nurs Forum 1995:22;73.
40. Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology, 4th ed. New York: McGraw-Hill, 1990.
41. Berkow R, Fletcher AJ, eds. The Merck manual of diagnosis and therapy, 16th ed. Rahway, NJ: Merck Research Laboratories, 1992.
42. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34.
43. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994;21(suppl 3):21-8.
44. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73:2535-42.
45. Skolnik A. As the blood supply gets safer, experts still call for ways to reduce the need for transfusions. JAMA 1992;268: 698-700.
46. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
47. Dodd RY. The risk of transfusion-transmitted infection [editorial]. N Engl J Med 1992;327:419-21.
48. Klein HG. Ten strategies to reduce blood loss in orthopedic surgery. Am J Surg 1995;170(suppl):21S-6.
49. Jensen LS, Aderson AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79:513-16.
50. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-18.
51. Mudido P, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996;36:860-5.
52. Sloand E, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34:48-53.
53. Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994:21(suppl 3):16-20.
54. Menitove JE. Transfusion-related immunomodulation in orthopedic surgery. In: Brecher ME, Jefferies LC, eds. Orthopedic transfusion therapy. Bethesda, MD: American Association of Blood Banks, 1995:43-63.
55. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In: Murphy MJ Jr, ed. Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing symposium. Dayton, OH: AlphaMed Press, 1991.
56. Data on file. Ortho Biotech Inc. Raritan, NJ.
57. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993;11:88-94.
58. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
59. Negrin R, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993;82:737-43.
60. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: results of a phase I/II clinical trial. Blood 1992;79:29-37.
61. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells 1993;11:348-55.
62. De Campos ES, Radford JA, Steward WP, Hill R, Thacher N. The effect of rHu erythropoietin (EPO) on levels of haemoglobin and number of red cell and platelet transfusions during intensive chemotherapy for small cell lung carcinoma (SCLC) [abstr]. Br J Cancer 1991;63(suppl 13):9.
63. Tsukuda M, Mochimatsu I, Nagahara T, et al. Clinical application of recombinant human erythropoietin for treatment in patients with head and neck cancer. Cancer Immunol Immunother 1993;36:52-6.
64. James RD, Wilkinson PM, Belli F, Welch R, Cowan R. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta Haematol 1992;87(suppl 1):12-15.
65. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-6.
66. Markman M, Reichman B, Hakes T, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993;49:172-6.
67. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer 1993;67:156-8.
68. Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62.
69. Vijayakumar S, Roach M III, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys 1993;26:721-9.
70. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:1147-52.
71. Oster W, Herrmann F, Gamm H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990;9:956-62.
72. Moliterno AR, Spivak JL. Anemia of cancer. Hematol Oncol Clin North Am 1996;10:345-63.
73. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European study group of erythropoietin (epoetin beta) treatment in multiple myeloma and non-Hodgkin's lymphoma. Blood 1996;87:2675-82.
74. Bolonaki I, Stiakaki E, Lydaki E, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pedaitr Hematol Oncol 1996;13:111-21.
75. Henry DH. Recombinant human erythropoietin treatment of anemic cancer patients. Cancer Pract 1996;4:180-4.
76. Wood PA, Hrushesky WJM. Erythropoietin usage in patients with cancer [commentary]. Cancer J Sci Am 1995;1:243-6.
77. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76:2319-29.
78. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
79. Surgenor DM, Wallace EL, Hao SH, Chapman RH. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990;322:1646-51.
80. Wallace E, Surgenor DM, Hao HS, An J, Chapman RH, Churchill WH. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion 1993;33:139-44.
81. Henry DH, Abels RI, Staddon AP, et al. Prospective evaluation of transfusion (tx) requirement in anemic cancer patients ± chemorx [abstr]. Blood 1990;76(suppl):401a.
82. American Red Cross, Council of Community Blood Centers, American Association of Blood Banks. Circular of information for the use of human blood and blood components. Bethesda, MD: Authors, 1994.
83. American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:403-6.
84. Standards Committee of the American Association of Blood Banks. Standards for blood banks and transfusion services, 17th ed. Bethesda, MD: American Association of Blood Banks, 1996.
85. Abels R, Larholt K, Nelson R, Young D. Risk of transfusion in small cell lung cancer patients receiving chemotherapy [abstr]. Blood 1994;84:664A.
86. Berdel WE, Danhauser-Riedl S, Oberberg D, Zafferani M. Effects of hematopoietic growth factors on malignant nonhematopoietic cells. Semin Oncol 1992;19:41-5.
87. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEPO) in anemia of malignancy. Haematologica 1996;81:434-41.
88. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84:1056-63.
89. Ortho Biotech Inc. Epoetin alfa (PROCRIT) package insert. Raritan, NJ; 1995.
90. Pavel JN. Red blood cell transfusions for anemia. Semin Oncol Nurs 1990;6:117-22.
91. Jain R. Use of blood transfusion in management of anemia. Med Clin North Am 1992;76:727-44.
92. Consensus Conference. Perioperative red blood cell transfusion. JAMA 1988;260:2700-3.
93. Sheffied R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997;31:15-22.
94. Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. Semin Oncol 1996;33(suppl 1):6-9.